LUCD Q1 2026 Earnings EPS Misses Estimates Amid PreRevenue Status RELL Q1 2026 Earnings EPS Beat Overshadowed by Weak Market Sentiment Day One Biopharmaceuticals DAWN Q4 2025 Earnings EPS Miss Reflects RD Spend Amid PreRevenue Status Amneal Pharmaceuticals Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency MSCI Q1 2026 Earnings Slight EPS Beat Supports Positive Market Response IE Q1 2026 Earnings WiderThanExpected Loss Despite Exploration Progress